Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XTX 301 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Xilio Therapeutics

Most Recent Events

  • 03 Oct 2025 According to Xilio Therapeutics media release, data from this trial including combination of Vilastobart and Atezolizumab in heavily pretreated Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland.
  • 09 Sep 2025 According to a Xilio media release, the company announced updated data from ongoing phase 1 trial of efarindodekin alfa, alongside the achievement of a dollars 17.5 million development milestone under its license agreement with Gilead Sciences, Inc.
  • 09 Sep 2025 Results (data cutoff date 2 Sep 2025) presented in an Xilio Therapeutics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top